Cambridge, UK: In vitro fertilisation (IVF) treatment is now a global affair which involves patients, fertility clinics, embryologists and transportation specialists. Each country has different legislation relating to fertility treatments, and with many patients now finding themselves seeking IVF in a country which supports their specific needs, it is crucial to securely and reliably transport the invaluable frozen eggs, sperms or embryos from one fertility clinic to another for further treatment cycles.
A patient was looking for a specialist courier to manage the transportation of frozen…
One Nucleus adds power and influence as senior AstraZeneca executive, Penny James joins the region’s life science membership organisation’s Board
Cambridge, UK: 28 April 2020: One Nucleus, the Cambridge based not-for-profit membership organisation for the East of England-London life sciences cluster, is delighted to announce the appointment of Penny James as a Non-Executive Director. Penny is Chief Operating Officer, Biopharmaceuticals R&D at AstraZeneca, a role she took up in February 2019.
Penny has 25 years’ experience working in pharmaceutical and chemical industries, having…
Cambridge, 27th April 2020: The Babraham Research Campus is delighted to confirm Eisai as the latest high-profile organisation to provide financial and mentoring support for its Accelerate@Babraham initiative. The additional funding will further enhance the ability of the Babraham Research Campus to drive innovation in early science concepts and nurture new life science companies within the Cambridge cluster.
First launched in 2018, the Accelerate@Babraham initiative supports ambitious early stage life science ventures by giving access to appropriate short-term open access laboratory and…
Cambridge, UK: Biocair, a specialist logistics company, has recently managed several urgent large-scale shipments of COVID-19 related protective equipment. The company is also supporting many companies and agencies with the swift transportation of testing kits, diagnostic specimens and medical devices.
The successful time-sensitive transportation of these materials requires expertise and experience in the global life sciences supply chain. Speaking about the role Biocair plays in the life sciences supply chain, Giuseppe Tricarico, Business Development Director, comments that “since the global…
Cambridge, UK, 22 April 2020: Horizon Discovery Group plc (LSE: HZD) (“Horizon”, “the Company” or “the Group”), a global leader in the application of gene editing and gene modulation for cell line engineering, today announced that its cGMP-compliant CHOSOURCE™ platform has played a key role in generating a stable cell line for the development of an immunotherapy for autoimmune diseases. Horizon’s pharmaceutical-grade, stable Chinese Hamster Ovary (CHO) cells delivered high yields of monoclonal antibody for LAG-3 immunotherapy, enabling Immutep and Batavia Biosciences to reach an important…
21 April 2020 | The UK Government has announced a ground-breaking new fund that will provide matched financing to UK start-ups and scale-ups.
Taylor Wessing played a leading role in advising the UK Government on the new fund, delivering an unprecedented funding solution in an expedited timeframe.
Angus Miln, partner and head of Taylor Wessing's Corporate Technology group, worked alongside Adrian Rainey and Adam Thatcher from Goodwin Proctor, and Aaron Archer from Cooley LLP and Ylan Steiner from Orrick, Herrington & Sutcliffe LLP.
Commenting on the project, Angus Miln…
Cambridge, UK, and Brisbane, CA, 21 April 2020 Mogrify Ltd (Mogrify®), a UK company aiming to transform the development of cell therapies by the systematic discovery of novel cell conversions, and Sangamo Therapeutics (Sangamo) (Nasdaq: SGMO), a genomic medicine company, today announced that they have executed a collaboration and exclusive license agreement for Sangamo to develop allogeneic cell therapies from Mogrify’s proprietary induced pluripotent stem cells (iPSCs) and embryonic stem cells (ESCs) and Sangamo’s zinc finger protein (ZFP) gene-engineered chimeric antigen receptor regulatory…
Stevenage Bioscience Catalyst (SBC), a leading location for development and commercialisation of cutting-edge therapeutics, is pleased to announce that Dr Hugo Villanueva is to join as Innovation and Business Development Director in May 2020.
Hugo joins us from Revenant Bio, a research organisation and consultancy supporting and attracting funding for start-ups, spinouts and growing companies in the life sciences sector and has experience of working with Clustermarket.
He is passionate about life science entrepreneurship and the commercialisation of research. As a founding member of the…
AMSBIO offer a trio of sterilization systems suitable for a range of applications from sterilizing small laboratory instruments to sterilizing large research facilities.These compact sterilizers use a mixture of ozone and UV to kill pathogenic organisms, including viruses, bacteria, and fungi. Ozone scrubbing technology enables the devices to convert ozone gas back to oxygen, giving you maximum protection against pathogens with minimum effort and zero risk.The CoolCLAVE™ Plus is a unique and innovative laboratory bench top sterilizer that is highly effective in keeping sterile, or…
London, UK, 20th April 2020 / Sciad Newswire / MicrofluidX announces it has raised £1.4m in seed funding from leading seed investors UK Innovation & Science Seed Fund (UKI2S), Longwall Ventures and Moulton Goodies Limited with angel contributions from 88 Capital and Cambridge Angels. The Company will develop its novel cell bioprocessing technology, utilising microfluidics to tackle the challenges associated with bioprocessing for cell and gene therapy.
MicrofluidX leverages the power of microfluidics to overcome the challenges of bioprocessing in the production of cell and gene therapies…